What are the diagnostic criteria for chronic erythrocytosis in a patient with a persistently elevated hematocrit of ≥58%?

Diagnostic Basis for Chronic Erythrocytosis

Chronic erythrocytosis is diagnosed when hemoglobin is ≥18.5 g/dL in men or ≥16.5 g/dL in women (or hematocrit at the 99th percentile for age/sex), confirmed on repeat testing to establish persistence. 1

Initial Diagnostic Threshold

The diagnosis begins with documenting sustained elevation of red blood cell parameters:

• Men: Hemoglobin ≥18.5 g/dL or Hematocrit ≥49%
• Women: Hemoglobin ≥16.5 g/dL or Hematocrit ≥48%

These values must be confirmed on repeat testing to distinguish true erythrocytosis from transient elevations 1, 2. With a hematocrit of ≥58%, your patient clearly meets this threshold.

Classification Framework

Once erythrocytosis is confirmed, the diagnostic workup follows this algorithmic approach:

Step 1: Distinguish Absolute vs. Relative Erythrocytosis

• Absolute erythrocytosis: Red cell mass >125% of predicted (true increase in red blood cells)
• Relative erythrocytosis: Normal red cell mass with plasma volume contraction 3, 4

Red cell mass measurement can clarify this distinction, though it's not always necessary if clinical context is clear.

Step 2: Measure Serum Erythropoietin Level

This is the critical branching point in the diagnostic algorithm 3, 5:

Low erythropoietin → Suggests primary erythrocytosis (bone marrow disorder)

• Proceed to JAK2 mutation testing
• Consider polycythemia vera (PV)

Normal or elevated erythropoietin → Suggests secondary erythrocytosis

• Investigate hypoxic causes (chronic lung disease, sleep apnea, high altitude)
• Look for erythropoietin-secreting tumors (renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma)
• Review medications (androgens, SGLT2 inhibitors, erythropoietin-stimulating agents)

Step 3: For Suspected Primary Erythrocytosis - Apply WHO Criteria for Polycythemia Vera

PV diagnosis requires EITHER:

• Both major criteria + one minor criterion, OR
• First major criterion + two minor criteria 1

Major Criteria:

1. Hemoglobin ≥18.5 g/dL (men) or ≥16.5 g/dL (women), OR documented sustained increase of ≥2 g/dL from baseline
2. Presence of JAK2 V617F or JAK2 exon 12 mutation (found in >90% of PV cases)

Minor Criteria:

1. Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis)
2. Serum erythropoietin below normal reference range
3. Endogenous erythroid colony formation in vitro

Key Clinical Discriminators

Look specifically for these features that distinguish PV from secondary causes 6:

Favoring PV:

• Splenomegaly (36% of cases)
• Thrombocytosis (53%) or leukocytosis (49%)
• Pruritus, especially after warm baths (33%)
• Erythromelalgia (burning pain in extremities, 5.3%)
• History of thrombosis (arterial 16%, venous 7% at diagnosis)
• JAK2 mutation positivity

Favoring Secondary Causes:

• Isolated erythrocytosis without leukocytosis/thrombocytosis
• Chronic hypoxemia (check oxygen saturation)
• Smoking history
• Sleep apnea symptoms
• High altitude residence
• Renal or hepatic masses on imaging

Common Pitfalls to Avoid

1. Don't assume PV without checking erythropoietin first - Secondary causes are actually more common than PV in general practice 2, 5

2. Don't skip JAK2 testing when erythropoietin is low - This mutation is present in >95% of PV cases and is now a major diagnostic criterion 1, 6

3. Don't forget to check for leukocytosis and thrombocytosis - Their presence strongly suggests a myeloproliferative neoplasm rather than secondary erythrocytosis 5

4. Don't overlook medication-induced erythrocytosis - SGLT2 inhibitors, androgens, and testosterone replacement are increasingly common culprits 5

5. In young patients or those with family history, consider congenital causes including hereditary erythrocytosis and erythropoietin receptor mutations 3, 4

Practical Diagnostic Algorithm

For your patient with hematocrit ≥58%:

1. Confirm persistence with repeat CBC
2. Order serum erythropoietin level immediately
3. Check JAK2 V617F mutation (especially if erythropoietin is low or if thrombocytosis/leukocytosis present)
4. Assess oxygen saturation and review for hypoxic conditions
5. Review complete blood count for thrombocytosis/leukocytosis
6. Examine for splenomegaly
7. If JAK2 positive with low erythropoietin → bone marrow biopsy to confirm PV and establish baseline before cytoreductive therapy 7

The WHO 2008 criteria 1 remain the gold standard for diagnosing PV, with JAK2 mutation testing representing the most significant advance in distinguishing primary from secondary erythrocytosis.